In vivo experiments showed that the tumor volume of the shRNA group was significantly smaller than that of the SC-shRNA group (P<0.01), the expression of CD46 and TREM1 was decreased considerably, and the expression of LC3B and ATG5 was higher (P<0.01). The gene discussed is MAP1LC3B; the disease is neoplasm.